JP Morgan Healthcare Conference
JP Morgan Healthcare Conference, Day 4: Elevation Oncology, Zymeworks, Achilles Therapeutics
On the fourth day, Elevation discussed its pipeline reorganization, Zymeworks talked about reallocating resources to early-stage products, and Achilles detailed progress on developing cell therapies.
EQRx Focuses Pipeline Strategy After Disappointing FDA Feedback on PD-L1 Inhibitor
The company has decided to stop developing sugemalimab, but is now focused on advancing its CDK4/6 and EGFR inhibitor programs.
JP Morgan Healthcare Conference, Day 3: Iovance Biotherapeutics, Biomea Fusion, ADC Therapeutics
Highlights from the third day included Iovance's regulatory plans for its TIL therapy and Biomea Fusion's efforts to advance its menin inhibitor in multiple indications.
JP Morgan Healthcare Conference, Day 2: Roche, Zai Lab, Revolution Medicines, Ideaya Biosciences
On the second day, Roche discussed its 2023 outlook, Revolution laid out its KRAS inhibitor development plans, and Ideaya said it would discuss study design for its PKC inhibitor with the FDA.
Natera Eyes Regulatory Path for Signatera as Companion Diagnostic
The firm isn't planning a strategy for a kitted version of the test, though company officials said they were open to that in the future.